A novel inactivated vaccine against Lawsonia intracellularis induces rapid induction of humoral immunity, reduction of bacterial shedding and provides robust gut barrier function

Citation for published version:

Digital Object Identifier (DOI):
10.1016/j.vaccine.2017.12.049

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Version created as part of publication process; publisher's layout; not normally made publicly available

Published In:
Vaccine

Publisher Rights Statement:
Under a Creative Commons license

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
A novel inactivated vaccine against *Lawsonia intracellularis* induces rapid induction of humoral immunity, reduction of bacterial shedding and provides robust gut barrier function

F. Roerink a,*, C.L. Morgan a, S.M. Knetter a, M.–H. Passat b, A.L. Archibald b, T. Ait-Ali b,†, E.L. Strait a

a Merck Animal Health, 2 Giralda Farms, Madison, NJ 07940, USA
b The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Easter Bush Campus, Roslin, Midlothian EH25 9RG, UK

**A R T I C L E   I N F O**

**Article info**

Received 11 September 2017
Received in revised form 8 December 2017
Accepted 18 December 2017
Available online xxxx

**Keywords:**
Swine
Ileitis
*Lawsonia intracellularis*
Intestinal integrity
Vaccine
Efficacy

**A B S T R A C T**

Porcine proliferative ileitis is a major economic burden for the swine industry, affecting growing pigs and young adult pigs. In this study, the protective efficacy of an inactivated, injectable whole-cell bacteria vaccine against *L. intracellularis* – Porcilis® Ileitis was evaluated under field conditions.

Eighty-five, three-week-old pigs on a commercial farrow-to-finish farm were vaccinated by the intramuscular route, either with a dose of injectable vaccine, or with saline. A subset of vaccines and control pigs were necropsied at 21 days post-challenge. Incidence and severity of ileitis were evaluated by gross and microscopic observation of ileal tissues. Colonization of the gut after challenge was examined by *L. intracellularis*-specific immunohistochemistry, and qPCR of ileal scrapings. Integrity of the intestinal barrier was evaluated to quantify a range of intestinal markers including secreted mucin and intestinal alkaline phosphatase, and innate immune markers including Caspase-3 and Calprotectin. A second subset of pigs was monitored for fecal shedding of *L. intracellularis*, until resolution of shedding.

Our investigation indicated that Porcilis Ileitis provided robust protection against ileitis, reduced bacterial shedding 15-fold (p < .05) and preserved normal gut barrier function in the face of an experimental challenge with virulent *L. intracellularis*.

© 2017 Published by Elsevier Ltd.

1. Introduction

Ileitis caused by *Lawsonia intracellularis* (*L. intracellularis*) continues to be a problem in swine production systems worldwide. *L. intracellularis* is a Gram-negative, intracellular bacterium that can infect a number of animal species, but it is of particular economic concern in the swine industry. In pigs, the bacteria cause porcine proliferative enteropathy (ileitis). Clinically affected animals exhibit diarrhea and reduced growth performance, resulting in increased time to market and greater variation in size between pigs. In young adults, the infection can lead to an acute hemorrhagic form of the disease, characterized by dark, tarry diarrhea and which may result in death. *L. intracellularis* also infects pigs sub-clinically, without clear clinical signs but still resulting in reduced growth performance. Its worldwide distribution and high prevalence have been recognized since the initial characterization of this pathogen in the early 1990s and *L. intracellularis* is reported to affect 57–100% of herds, globally [1–3].

As an obligate intracellular pathogen, interaction between *L. intracellularis* and host cells is crucial in establishing infection. The bacterium infects the gastrointestinal tract, with a specific tropism for the terminal ileum. The hallmark lesion of *L. intracellularis* infection is the proliferation of intestinal crypt lining cells (enterocytes) which results in hyperplasia of the mucosal wall. The peak of bacterial burden is associated not only with crypt epithelial cell proliferation but also with down-regulation of specific host mechanisms involved in cell transport and maintenance of mucosal integrity, and with inflammation [4–6]. It is likely that the poor performance and growth of affected animals are a direct consequence of these cell differentiation alterations [7].

There are some tools available for controlling *L. intracellularis* infections and limiting the associated economic losses. Infection by the bacterium can be treated with various antibiotics, notably those from the macrolide, pleuromutilin, and quinoxaline groups [7]. For prophylaxis, a modified live-attenuated vaccine has been commercially available since 2001 [8]. Due to the live nature of the oral vaccine, concurrent use with antibiotics effective against
**L. intracellularis** is not possible. The use of the oral vaccine requires strict management practices to avoid the simultaneous use of antibiotic treatments. However, prophylactic use of an inactivated vaccine would not be limited in this way.

In this study, the effectiveness of a novel inactivated injectable vaccine, Porcilis Ileitis, as an aid in the control of ileitis caused by *L. intracellularis* was examined. This vaccine was administered to three-week-old pigs under typical field conditions, without restricting the use of antibiotics. Our investigation indicates that Porcilis Ileitis vaccine can provide robust protection against ileitis, help reduce bacterial shedding 15-fold (*p < .01*), and help maintain gut barrier function integrity.

2. Materials and methods

2.1. Ethical statement

The animal trial was conducted by Swine Services Unlimited (Rice, MN, USA, SSUI) as a randomized, blinded study, approved by the SSUI Institutional Animal Care and Use Committee.

2.2. Vaccine

The vaccine used in this study contained inactivated *L. intracellularis* bacteria in XSOLVE adjuvant (Porcilis Ileitis, serial 02381108, Merck Animal Health, Madison, NJ USA). The vaccine is an oil-in-water emulsion. The adjuvant is based on both mineral oil and alpha tocopherol (Vitamin E).

2.3. Study design

Eighty-five mixed-breed and mixed-sex pigs were enrolled on a commercial, farrow-to-finish farm, which farrowed 30 litters per week, weaning 300 pigs per week. The herd was health-stable prior to and during the study, with historic pre-weaning mortality rates between 8 and 10% during the previous 2 years, and nursery mortality of approximately 3%. The herd did not show clinical signs of *L. intracellularis* infection, and all study pigs were negative for anti-*L. intracellularis* antibodies as measured by a commercial inhibition ELISA (bioScreen Ileitis Antibody ELISA, Svanova, Sweden).

The study design is summarized in Fig. 1. Pigs were allocated to the treatments using a random number generator, so that both vaccines and placebo injected controls were represented within all litters. At 22–25 days of age (23 days median), 40 pigs were given a single 2 mL vaccination intramuscularly in the neck, using a 20 gauge, ½ in. needle. Another 40 pigs were injected with 2 mL of normal saline as a control. Five pigs were allocated to a sentinel group, and these pigs were administered normal saline in the same manner as the control pigs.

The pigs were weaned one day after their vaccination. Upon weaning, the pigs were transported to isolation facilities for the pre-challenge and challenge phases of the study. Pigs from each group were comingled with approximately equal numbers of vaccines and controls in each pen.

Prior to the challenge, the treatment groups were divided randomly into a subset of 25 pigs to be necropsied at 21 days post-challenge (dpc) (necropsy groups), and a subset of 15 pigs to be fecal sampled to determine *L. intracellularis* shedding during the post-challenge period (sampling groups, see Fig. 1). Randomization was performed using the Microsoft Excel function Rand() [9]. Challenge occurred five weeks post-vaccination, when the pigs were approximately 8 weeks of age. The timing of necropsy was chosen based on published results of experimental infections [7,10] and coincided with the peak time of fecal shedding and ileal lesions found in preliminary experiments with this challenge model (data not shown).

Prior to the start of the study, as well as prior to the challenge, all pigs were bled and sera were prepared. Pigs were bled again at the end of the test, at 21 dpc for the necropsy groups and at 51 dpc for the shedding groups.

2.4. Husbandry

Water was provided *ad libitum* to all animals. Feed met or exceeded the minimum nutritional requirements for animals of this age and complied with standard procedures for the site. During the pre-weaning phase, the piglets had access to the dam’s feed and water dispensers. Sow feed during this phase was a standard, non-medicated lactation diet. Feed was medicated with Mecadox (carbadox) at 50 g/ton, from the day after the vaccination when the pigs were weaned, until two weeks later (14 dpv). Carbadox is a quinoloxaline antibiotic indicated for the control of swine dysentery and control of bacterial swine enteritis caused by *Salmonella choleraesuis*, but also effective against *L. intracellularis*, with a reported intracellular minimum inhibitory concentration of <0.5 μg/mL [11,12]. Three weeks after weaning, mild loose stools were observed in some of the pens. All pigs were therefore treated for three days with gentamicin between 22 and 24 dpv. This medication was administered through the water supply, at 1 mg/pig/day. Two pigs were removed from the study at 9 and 12 dpv due to head-tilt and ataxia. Both pigs were allocated in the vaccinated necropsy group. Diagnostic work-ups resulted in diagnoses of bacterial meningitis and possible otitis media, considered unrelated to the vaccination.

2.5. Challenge

2.5.1. Challenge material

At the time of challenge, the five sentinel pigs were necropsied and evaluated for evidence of *L. intracellularis* exposure as detailed in Section 2.8 Necropsy. The remaining 80 pigs were individually orally challenged by syringe into the back of the mouth with 25 mL of *L. intracellularis*-infected gut homogenate, containing approximately 9.3 Log10 of *L. intracellularis*, as determined by qPCR. The gut homogenate was prepared from intestines of pigs experimentally challenged with a virulent isolate obtained in 2008 from pigs in the United States displaying clinical signs of ileitis. Briefly, mucosa from guts of pigs with clinical signs of ileitis were collected by scraping, diluted in sucrose-phosphate-glutamate buffer,
considered suspect, and 30% and higher indicate positive results.

2.5.2. Scoring of clinical signs of ileitis

Following the challenge, all pigs were observed daily for clinical signs of ileitis, including body condition, alertness, appetite, and consistency of the feces. Fecal consistency was scored as normal, soft or watery (mild diarrhea), bloody or tarry (severe diarrhea).

2.6. Serology

Five to 10 mL blood was collected in serum separator tubes, and centrifuged as recommended by the manufacturer, usually for 20 min at 860g. Sera were collected and stored frozen at −20 °C or lower until testing by a commercial competitive ELISA as documented in Section 2.3 [14]. Results are reported as percent (%) inhibition. Per the manufacturer’s instructions, results below 20% are negative for *L. intracellularis* antibodies, between 20 and 30% are considered suspect, and 30% and higher indicate positive results.

2.7. Quantitative real-time PCR

Quantitative real-time PCR (qPCR) of ileal scrapings and fecal samples was conducted at the Iowa State University Veterinary Diagnostic Laboratory, according to previous standard methods [15]. Briefly, the region (nucleotide 583–680) of the 16S rDNA gene of *L. intracellularis* (GenBank accession # L157390) was monitored with the forward primer, 5′-GGCGCGTAGGTTGATAT-3′, the reverse primer, 5′-GCCACCTCTCGGATACCT-3′ and the fluorescent probe 5′-FAM-CACCGCTTAACGGTGGAACAGCCTT-TAMRA-3′. The qPCR conditions were as described previously [15]. Results (Ct values) were reported as the cycle number where fluorescence exceeded the threshold value. All assays continued for 40 cycles. In order to calculate the amount of *L. intracellularis* present in the samples and to evaluate the treatment effect, Ct values were transformed to copies per reaction (c/rx) by assuming that 40 Ct represents absence of *L. intracellularis* DNA (0 c/rx), and assuming 100% efficiency of replication, resulting in a 10-fold increase of DNA for every 3.3 cycles reduction in Ct values. Calculations were therefore carried out as follows: c/rx = 2^(-40+Ct).

2.8. Necropsy

The sentinel pigs were necropsied at the time of the challenge, while the necropsy groups were sacrificed at 21 dpc. In each case, the ileum was opened longitudinally, and gross lesions of ileitis were scored. Mucosa were scraped using a glass slide into a 50 mL conical tube, and the collected material was snap-frozen on dry ice and stored at −70 °C until further processing such as the determination of the level of *L. intracellularis* in intestinal epithelial cells as measured by qPCR. Furthermore, a tissue sample was fixed in buffered neutral formalin for microscopic evaluations as described below.

2.8.1. Gross lesion scoring

Gross lesions were scored on the basis of the severity of mucosal thickening (0- normal, 1- slight edema/hyperemia, 2- moderate hyperemia/mucosal thickening, 3- severe mucosal thickening, 4- severe hemorrhaging/necrosis/fibrous exudate). Scores 2–4 were considered indicative of clinical ileitis.

2.8.2. Histopathology for *L. intracellularis*

Formalin-fixed tissues were submitted to the Iowa State University Veterinary Diagnostic Laboratory for standard histopathological examination following Haematoxylin-Eosin (H&E) staining to evaluate microscopic lesions, mainly proliferation, consistent with *L. intracellularis* (0- no lesions; 1- mild proliferation; 2- marked proliferative enterocolitis).

2.8.3. PAS staining

For PAS staining, fixed tissues were deparaffinized and rehydrated, immersed in periodic acid and stained with Schiff’s reagent as described previously [6].

2.8.4. Immunofluorescence

For immunofluorescence (IF) all the antibodies tested (Supplementary Table 1) except for anti-*L. intracellularis* antibody required heat-mediated antigen retrieval in citrate buffer at pH6, using a Histostain Rapid Microwave Histoprocessor (Milestone) with the following protocol: high pressure treatment at 110 °C for 5 min (20...
3. Results

3.1. Reduction of signs of clinical disease in vaccinated pigs

All pigs were individually observed every other day for three weeks following vaccination for any evidence of adverse systemic or injection site reactions. No systemic adverse reactions to the vaccination were observed. Local injection site reactions were observed in 10 of 40 (25%) vaccinated animals, ranging in size between 1 × 1 cm and 4 × 4 cm (length × width). All local reactions resolved by 19 days post-vaccination (dpv) without intervention.

Signs of clinical disease were monitored during the challenge phase of the experiment. Severe diarrhea was observed in 16 of 40 animals in the control group (40%), but not in any of the 40 vaccinated animals. In the vaccinated group, 11 of 40 animals (28%) presented with mild diarrhea at any time during the post-challenge period. Loss of appetite, lethargy or ill thrift was recorded for four control pigs.

Ileum gross lesion scoring is summarized in Fig. 2A. In the control group, 17 of 25 pigs (68%) were scored as positive (score >1), whereas only 2 of the 23 vaccinated pigs (9%) were scored as positive. Seven of the 25 control animals (28%) were given a score of 3 or 4, indicating severe ileitis, while none of the vaccinated pigs had scores higher than 2. The incidence of gross lesions of ileitis in the vaccinated group was significantly reduced compared to the control group (p < .0001).

The occurrence of clinical ileitis was also evaluated by histopathological examination, on an ordinal scale 0–2 (Fig. 2B). Of the 25 controls, 22 (88%) were positive (score >0), with 3 pigs presenting with score 1 and 19 pigs with score 2. Of the vaccinated group, 10 of 23 (43%) were positive for microscopic lesions. Overall the incidence of microscopic lesions of ileitis in the vaccinated group was significantly reduced compared to the control group (p = .0018).

3.2. Reduction of bacterial load in ileum of vaccinated pigs

Colonization of the small intestines was evaluated in the necropsy group at 21 dpc by qPCR of the ileal scrapings and L. intracellularis-specific IF. Results are shown in Fig. 3. All animals were positive by qPCR on ileal scrapings (Fig. 3A); however, the average L. intracellularis DNA load of vaccinated pigs was significantly lower than that of the control pigs (geometric mean titer GMT: 5.0 × 10^4 vs 1.1 × 10^7 c/rx, p < .0001). Using IF of L. intracellularis specific antigen VPM53, intestinal crypt cells of controls harbored significantly greater bacterial load associated with enhanced cell proliferation than vaccinated pigs (p < .001) (Fig. 3B and C).

3.3. Vaccination induces anti-L. Intracellularis serum antibodies

Vaccinated and control pigs were monitored for anti-L. intracellularis serological profiles using an inhibition assay (Fig. 4). Vaccinated pigs harbored significantly higher levels of anti-L. intracellularis antibodies prior to challenge than controls (p < .0001). Following challenge, all control pigs developed anti-L. intracellularis antibodies similar to vaccinated pigs as monitored at 21 and 51 dpc (p > .05).

3.4. Gut integrity is maintained in vaccinates

To assess the integrity of the ileum tissues collected at 21 dpc, a range of intestinal cell lineage markers was evaluated and quantified. In particular, molecular markers that identify secretion (PAS signal and Mucin2, MUC2), absorption and homeostasis (Intestinal alkaline phosphatase, IAP), apoptosis (Cleaved-caspase3, CASP3) and immune cell distribution (Calprotectin, CP) were monitored (Figs. 5 and 6) [6,16,18–20]. In the vaccinated group (n = 23) the level of PAS, MUC2 as well as IAP was significantly higher than controls (n = 25; p < .01, p < .01, p < .001, respectively). IAP expression in vaccinated pigs was similar to the level found in the sentinels (n = 5; p > .05). Expression of apoptotic marker CASP3 was significantly up-regulated in controls (p < .05) pigs compared to the sentinels. CP, a marker associated with neutrophil infiltration, was expressed at a higher level compared to the sentinels, in both controls (p > .05) and vaccinates (p < .05).

3.5. Fifteen-fold reduction of L. intracellularis fecal shedding in vaccinates

Fecal shedding was monitored in a subset of the vaccinated (n = 15) and control (n = 15) animals using qPCR over 51 dpc (Fig. 7A). The mean daily average amount of L. intracellularis shed during the 51 dpc was 6.2 × 10^5 copies/reaction/day for the control group, and 4.1 × 10^4 per day for the test vaccine animals,
representing a 15-fold reduction ($p < .05$, Fig. 7B). Overall, the median duration of shedding was significantly reduced in the vaccinated group by 4.4 days ($p < .05$, data not shown). The median time point where maximum shedding occurred was also earlier in vaccines (14 dpc versus 23 dpc), although this difference was not statistically significant ($p > .05$).

4. Discussion

In this study, we have assessed the efficacy of a novel inactivated, injectable whole-cell bacteria vaccine against *L. intracellularis* – Porcilis Ileitis. We found that this adjuvanted *L. intracellularis* vaccine was safe in pigs when administered under typical field conditions at three weeks of age prior to weaning. Following challenge, signs of severe clinical ileitis were observed in 40% of the controls, but not in the vaccinated pigs. Protection of vaccines was further confirmed by gross observation of the ileum, as well as histopathology. For each of these parameters, significantly more control animals were affected than vaccinated animals. Taken together these results indicate that the vaccine reduced both the incidence and severity of clinical signs.

At the time of vaccination nearly all of the animals tested negative for anti-*L. intracellularis* antibodies by ELISA, although three of 85 pigs had test results which were classified as ‘suspect’ by the manufacturer’s criteria, most likely as a result of low levels of maternally-derived antibodies against *L. intracellularis*. The ‘suspect’ animals were included in the analyses. Vaccinated pigs displayed an antibody response in the majority of pigs, in spite of the vaccine regimen consisting of only a single dose. At three weeks post-vaccination, 75% of vaccines were classified as suspect or positive. No apparent correlations were found between sero-response following vaccination and outcome parameters of the challenge, such as clinical signs, gross lesions, microscopic scores or PCR results (data not shown). This suggests that at least part of the protective mechanism of this inactivated, parenteral vaccine may be through induction of cell-mediated immunity (CMI) as previously described for other bacterial pathogens, such as *Mycoplasma hyopneumoniae* [21–23]. Further investigation is required to assess if this is the case.

Our study clearly showed that reduced clinical signs in vaccines coincided with a reduced bacterial load and increased ileum integrity at 21 dpc, compared to nonvaccinated controls. The bacterial load was significantly (200-fold) reduced in the terminal ileum as determined by qPCR, and was significantly lower when examined by *L. intracellularis*-specific IF. Bacterial loads were also significantly lower in the feces of vaccinated animals, both in terms of reduced severity (bacteria shed per day) and in reduction of the duration of fecal shedding. Reduced proliferation of enterocytes in vaccinated pigs compared to controls, as demonstrated by H&E staining of ileum tissues, coincided with significantly greater numbers of MUC2-expressing goblet cells and IAP-expressing brush border cells than controls indicating a restoration of these essential intestinal cell lineages [6,16,18–20]. Similarly, the level of cleaved-CASP3 in lumen of the ileum of vaccinated pigs was, at least in part, reduced to the level observed in sentinel pigs. This may indicate a possible reduction in apoptosis mechanisms as previously described [16]. In contrast, we found that the induction of CP, a marker of neutrophil and macrophage infiltration, was still noticeably expressed in the ileum of vaccinated pigs, perhaps indicating that innate immune cells were actively patrolling the lamina propria at 21 dpc [24]. Taken together, the monitoring of these intestinal cell lineages and immune markers supports an immunization mechanism whereby the vaccination not only prevented infection by *L. intracellularis* of the crypt cells, but also helped preserve normal mucosal architecture and homeostasis.

According to Johansen et al. [25], diarrhea is a significant risk factor for low growth rate in pigs, and a 10-fold increase in fecal load of *L. intracellularis* increases the odds ratio for low growth rate by 2. In this study, fecal shed in the vaccines was reduced 15-fold compared to the controls. Although this study did not record growth parameters, the vaccination can be expected to have prevented the negative impacts of *L. intracellularis* infection on the economic parameters of this cohort of pigs.

The use of a killed Lawsonia in this study allowed the administration of antibiotics to the pigs around the time of the vaccination. The vaccine was compatible with the use of carbadox administered in the feed as early as one day after vaccination, as demonstrated by the protection that was shown against virulent challenge compared with non-vaccinated control pigs.

In conclusion, the data demonstrated that this inactivated, adjuvanted *L. intracellularis* vaccine was safe in pigs when administered under typical field conditions as a single, 2 mL dose at three weeks.
of age prior to weaning. The study demonstrated that the vaccine reduced both the incidence and severity of clinical signs of ileitis due to *L. intracellularis*, reduced colonization by *L. intracellularis*, and reduced the severity and duration of fecal shedding of *L. intracellularis*. The study also found that gut function in the face of *L. intracellularis* infection was improved following vaccination.

Fig. 6. Scatterplot of PAS, IAP and IF signals for MUC2, CASP3 and CP. Scatterplot of staining signal intensities obtained using Image J software for sentinel, control and vaccinate ileum crypts at 21 dpc. Image quantification was performed as described in materials and methods section. For statistical analysis between groups a 1-way ANOVA was used as previously described. Group median values and P-values are shown when *p* < .05. For MUC2 and PAS staining 4 sentinels instead of 5 were used because one paraffin-block was missing at the time of the staining. Missing pig section was not assessed because of the relatively small spread between data. Y-axis represents fluorescence signal intensity of the marker staining per section.
Conflict of interest

This study was funded by Merck Animal Health, Madison, NJ USA. The animal trial was designed by FR and ES. End-of-study lesion scoring was conducted by FR while blinded to the grouping. M-HP, AA and TA-A declare no conflict of interest.

Acknowledgements

The authors wish to thank Swine Services Unlimited, Inc, Rice, MN, USA for expert animal care and veterinary services during the study, and Dr. Vicki Cooper, Iowa State University Veterinary Diagnostic Laboratory, for her technical and organizational assistance with the laboratory tests. Further we would like to express our sincere gratitude to Professor Liz Glass, The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, for providing useful comments. AA and TA-A acknowledge support from BBSRC Institute Strategic Programme grants (BB/J004227/1, BB/P013740/1).

Appendix A. Supplementary material

Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.vaccine.2017.12.049.

Fig. 7. L. intracellularis fecal shedding. (A) Daily amount and standard deviation of L. intracellularis (LI) fecal shedding as determined by qPCR on fecal samples collected three times weekly until resolution of all shedding. (B) The daily average amount of L. intracellularis shed during the 51 day post-challenge observation period. Group mean values are indicated, and p-values when p < .05.

References


